MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pasithea Therapeutics Corp. - Common Stock (NQ:KTTA)

1.120 -0.010 (-0.87%)
Streaming Delayed Price Updated: 12:43 PM EST, Dec 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pasithea Therapeutics Corp. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
A New BioTech Research Race Is Focused On Improving Life For MS Patients ↗
When the world is focused on a global pandemic no one saw coming four years ago, the attention given to escalating diseases with no known cure can be hidden from the public consciousness. This is... 
Via Benzinga
News headline image
Pasithea' Largest Investor Group Says AlloMek Therapeutics Deal Ill-timed, Highly Dilutive ↗
 
Via Benzinga
News headline image
Investor Group Comments on Pasithea Therapeutics’ Seemingly Defensive and Ill-Timed Acquisition of AlloMek Therapeutics
From Camac Partners, LLC and Affiliates of Concord Investment Partners Ltd. and Leonite Capital LLC
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Gainers 
Via Benzinga
Biotech Company Pleased With Results Of Early Testing Demonstrating Vaccine Potential For Multiple Sclerosis
Learn More about Pasithea Therapeutics by gaining access to the latest research report 
Via TheNewswire.com
Pasithea Therapeutics Awarded A Drug Development Research Grant ↗
-- AUD $1 million (U.S $694,000) grant transferred as part of Alpha-5 Integrin, LLC transaction -- -- Provides approximately U.S. $694,000 of non-dilutive funding -- 
Via Benzinga
Central Nervous System Disorders Therapeutics Market Expected to Reach $159 Billion by 2028
Palm Beach, FL –– October 12, 2022 – FinancialNewsMedia.com News Commentary – The COVID pandemic has not only had a negative effect on most markets but it has also spurred growth in several worldwide... 
Via FinancialNewsMedia
News headline image
EXCLUSIVE: Pasithea Bolsters CNS-Focused Pipeline With AlloMek Therapeutics Acquisition ↗
Pasithea Therapeutics Corp (NASDAQ: KTTA) has acquired AlloMek Therapeutics LLC, a privately-held biotechnology company,  
Via Benzinga
News headline image
New Drugs And Therapies Are Giving MS And ALS Sufferers New Hope ↗
People suffering from incurable neurological diseases such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) hope new therapies and drugs will arrive sooner than later.    
Via Benzinga
News headline image
Biotech Company Pleased With Results Of Early Testing Demonstrating Vaccine Potential For Multiple Sclerosis
By Mark Gilman, Benzinga 
Via News Direct
News headline image
Biotech Company Pleased With Results Of Early Testing Demonstrating Vaccine Potential For Multiple Sclerosis ↗
Vaccines that boost the body’s immune system against foreign proteins are different than those that are an inverse vaccine fighting an autoimmune disease. 
Via Benzinga
Ron Bauer, Author of Exit Plan: How to Raise Money & Go Public, has a book release planned for December 2022
Via Get News
News headline image
Investor Group Sends Letter to Pasithea Therapeutics’ Board of Directors
From Camac Partners, LLC and Affiliates of Concord Investment Partners Ltd. and Leonite Capital LLC
Via Business Wire
News headline image
Investor Group Successful in Request to Call Special Meeting of Stockholders of Pasithea Therapeutics
From Camac Partners, LLC, Affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
  
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
  
Via Benzinga
News headline image
Investor Group Urges Stockholders of Pasithea Therapeutics to Vote to Call Special Meeting
From CAMAC PARTNERS, LLC, AFFILIATES OF CONCORD INVESTMENT PARTNERS LTD., AND LEONITE CAPITAL LLC
Via Business Wire
Global Multiple Sclerosis Drugs Market Size Projected To Reach $33 Billion By 2029
Palm Beach, FL –– August 11, 2022 – FinancialNewsMedia.com News Commentary – Multiple Sclerosis (MS) is an immune-mediated disease affecting the central nervous system. It is characterized by... 
Via FinancialNewsMedia
News headline image
EXCLUSIVE: Pasithea's Multiple Sclerosis Vaccine Candidate Shows Efficacy In Animal Studies, With Potential In Monkeypox ↗
Pasithea Therapeutics Corp (NASDAQ: KTTA) has announced results from a preliminary preclinical proof of concept study of PAS002, its tolerizing vaccine for multiple sclerosis (MS). 
Via Benzinga
News headline image
Smaller Biotechs May Pave Way For New Generation Of Therapeutics For Hard-to-Treat Neurological Disorders ↗
An estimated 200 million Americans — more than 60% of the population — suffer from at least one neurological disorder. That includes dementia, strokes, migraines and other diseases or infections that... 
Via Benzinga
News headline image
Investor Group Urges Stockholders of Pasithea Therapeutics Corp. to Call Special Meeting
From CAMAC PARTNERS, LLC, AFFILIATES OF CONCORD INVESTMENT PARTNERS LTD., AND LEONITE CAPITAL LLC.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Gainers Applied DNA Sciences (NASDAQ:APDN) stock rose 90.0% to $5.32 during Tuesday's after-market session. At the close, Applied DNA Sciences's trading volume reached 28.8 million shares. This is... 
Via Benzinga
News headline image
A Monoclonal Antibody Treatment For ALS Could Begin Human Trials By 2023, According To Pasithea ↗
Pasithea Therapeutics Corp. (NASDAQ: KTTA), a biotech company looking for new treatments for psychiatric and neurological disorders, received an AU$1 million (US$694,000) gran 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Gainers 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares increased by 15.1% to $0.63 during Wednesday's after-market session. The company's market cap stands at $16.7 million. 
Via Benzinga
News headline image
Pasithea's Latest Drug Candidate Could Bring New Hope To ALS Patients Without Effective Treatment Options ↗
Amyotrophic lateral sclerosis (ALS) is a rare but painful and fatal disease that slowly shuts down all voluntary movements in the body, from walking to breathing. 
Via Benzinga
News headline image
Pasithea Therapeutics Receives AUD $1 Million Research Award Following Recent Acquisition ↗
Pasithea Therapeutics Corp. (NASDAQ: KTTA) recently announced the availability of an AUD $1 million (USD $694,000) drug development research award following the Company's acquisition of Alpha-5... 
Via Benzinga
News headline image
This Biotech Company Says That It's Looking To Deliver A Breakthrough In Psychiatric Medicine — What's The Scoop? ↗
Pasithea Therapeutics Corp. (NASDAQ: KTTA) is a biotech company with a goal of investigating novel drug treatments to provide more effective relief to the estimated 792 million people around the world... 
Via Benzinga
News headline image
Investor Group Comments on Pasithea Therapeutics’ Seemingly Defensive and Dilutive Related-Party Acquisition of Alpha-5
From Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC
Via Business Wire
Revenues From Treatment of Rare Neurological Disorders Worldwide Are Poised to Surpass $12 Billion in 2026
Palm Beach, FL – June 22, 2022 – FinancialNewsMedia.com News Commentary Neuroinflammatory disorder is the study of conditions where immune responses which damage components of the nervous system. It... 
Via FinancialNewsMedia
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story